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 Borrelia burgdorferi and Borrelia hermsii cause Lyme disease and relapsing 
fever, respectively. These spirochetes are maintained in an enzootic cycle, involving tick 
vectors and mammalian hosts. Differential gene expression is central in their survival in 
various environmental conditions. C-di-GMP has been demonstrated to be important in 
bacterial adaptation. Borrelia deletion mutant phenotypes have shown that c-di-GMP 
regulates motility, infectivity, and enzootic cycle progression. As the only known 
receptors encoded by Borrelia, PlzA and PlzC characterization is necessary in 
delineating c-di-GMP roles within the cell. In this study, biochemical, biophysical, and 
FRET methods demonstrated that these proteins exhibit a structural rearrangement 
when binding c-di-GMP likely significant to downstream activities. Substitution of a 
highly conserved residue within PlzA altered the structure and charge of the PilZ 
ix
domain, leading to abolished binding. PlzA and PlzC functionality studies are vital to 
discover mechanisms of c-di-GMP-mediated regulation of motility and host invasion by 
the Borrelia. 
 
x
  
Chapter 1: Introduction 
 
Borrelia genus 
The genus Borrelia contains a group of enigmatic bacterial species which are 
defined by many unique properties. Despite being Gram-negative, the Borrelia lack the 
lipopolysaccharides characteristic of most Gram-negative species (134). They have 
developed highly fragmented genomes, consisting of a linear chromosome and multiple 
linear and circular plasmids (11, 13). In addition to fragmentation, Borrelia genomes 
have severely reduced metabolic and biosynthetic genetic information, making them 
highly reliant on their hosts for nutrients and basic metabolites (52, 99). These species 
have a distinct spiral morphology, the architecture of which is generated by the polar 
flagellar bundles (16). This spiral shape confers a very unique motility phenotype and 
contributes to infectivity (74, 130). Despite and because of these unusual properties, 
Borrelia species cause multiple infections across a range of mammalian, reptilian, 
avian, and arthropod hosts. 
Most motile bacteria have external flagella or cilia to allow for translational motion 
(18). However, the Borrelia are unique in that their flagella are contained within the 
periplasmic space between the outer and cytoplasmic membrane depicted in Figure 1-
1. These flagellar bundles are comprised of seven to eleven filaments insert into the 
cytoplasmic membrane at each end of the bacterium (75). These filaments form flat 
1
Figure 1-1. Borrelia periplasmic flagellla.  The top panel is a depiction of a spirochete 
with an outer and cytoplasmic membrane, between which lies the periplasmic space. 
The unique, internal flagella wind around the protoplasmic cylinder, generating the 
spirochete morphology. The bottom panel shows the flagellum inserted into the 
cytoplasmic membrane by the flagellar motor.
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ribbons and wind around the cell cylinder to generate the characteristic shape of these 
spirochetes (102). Each flagellum anchors into the cytoplasmic membrane by a motor 
complex that controls the rotational motion of the flagellum (75). Each of these motors is 
capable of clockwise and counter-clockwise rotation, which results in a “tumble” or “run” 
motility in most bacteria (18). However, due to the internal flagellar bundles at each 
pole, the Borrelia exhibit a “run,” “flex,” and “reverse” phenotype shown in Figure 1-2 
(83). The “run” is when both flagellar motors are rotating in opposite directions and 
results in a corkscrew-like motility. When one bundle changes flagellar rotation, a 
spasming of the bacterium occurs. This is referred to as a “flex” and is a pause in 
translational motion, much like a “tumble” (18, 83). When the bundles are rotating 
asymmetrically once more, but in the opposite direction of the original “run,” it is a 
“reverse.” This motility pattern allows spirochetes to migrate through highly viscous 
environments such as connective tissue and contributes to pathogenicity (36, 68, 75, 
130). 
Two major branches exist within the Borrelia genus and these are defined by the 
diseases that the bacteria cause. One branch encompasses the Lyme disease-causing 
species, including B. afzelii, B. americana, B. andersonii, B. bavariensis, B. bissettii, B. 
burgdorferi, B. californiensis, B. carolinensis, B. garinii, B. japonica, B. kurtenbachii, B. 
lusitaniae, B. sinica, B. tanukii, B. turdi, B. spielmanii, B. valaisiana, and B. yangtze 
(112). The other branch contains the relapsing fever spirochetes, B. hermsii, B. 
turicatae, B. duttonii, B. dugesi, B. crocidurae, B. parkeri, and B. recurrentis (41, 47). All 
of the listed species are tick-borne pathogens with the exception of B. recurrentis, which 
is spread by the human body louse, Pediculus humanus humanus (47). The work 
3
Figure 1-2. Spirochete motility controlled by flagellar rotational direction. The 
“run,” “flex,” and “reverse” motility of the spirochete is dependent on the rotational 
direction of the polar flagellar bundles. The top image shows the “run” phenotype where 
each pole is rotating in opposite directions. This allows translational motion to the right. 
The image below that is with the asymmetrical rotation of the flagella in the opposite 
direction of the “run” which results in a “reverse” and translation motion to the left. The 
bottom two images show the bundles rotating in the same directions, which presents as 
a “flex.”
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contained within this thesis is concentrated on two species of Borrelia to represent the 
two branches within the genus, B. burgdorferi as a part of the Lyme disease branch and 
B. hermsii of the tick-borne relapsing fever branch. Both of these species are the most 
common cause of their respective diseases in North America. 
 
Lyme disease 
Lyme borreliosis is an emerging infectious disease that first made its debut in the 
mid-1970s near Lyme, CT (128).  The disease was associated with severe arthritis and 
an expanding “bull’s eye” rash, previously described by Arvid Afzelius in 1909 (2). He 
observed it in relation to the bite of a hard-bodied tick and named this lesion the 
‘erythema migrans’ rash. In addition to this dermatological manifestation, patients of the 
Lyme epidemic developed neurological, articular, and cardiac abnormalities (51, 85, 
104, 127). These disease symptoms were associated with the bite of the Ixodes 
scapularis tick and, later, with the presence of a B. burgdorferi infection (27). Soon after, 
B. burgdorferi was isolated from the reservoir species, Peromyscus leucupus and the 
tick-mouse transmission confirmed (17, 24, 29). Since then, Lyme disease has been 
diagnosed in North America, Europe, and Asia with three major species causing the 
disease. Two of these (B. garinii and B. afzelii) are only present in Europe and Asia and 
spread by the Ixodes ricinus and Ixodes persulcatus ticks.  In North America, B. 
burgdorferi is the primary causative agent and is spread by I. scapularis and Ixodes 
pacificus (28, 30, 64, 90). 
In the United States, Lyme disease is the most common vector-borne disease 
and the sixth most common nationally notifiable disease (1, 34). In 2011, there were 
5
33,097 confirmed and probable cases according to the CDC. This makes the national 
incidence rate 7.8 per 100,000 population (34). These statistics are considered to be 
under-representative of actual infection numbers due to severe under-reporting and 
misdiagnosis (33, 145). Additionally, 96% of the cases occurred in specific geographical 
regions, the Northeast, mid-Atlantic, and upper Midwest; this is shown in Figure 1-3 
(34). The reported incidence of individual states per 100,000 was as high as 84.6 
(Delaware) and was 28.7 between the 14 states that are considered to be part of the 
endemic regions: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, 
New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, 
Virginia, and Wisconsin (individual state statistics can be found in Table 1-1) (34). 
Lyme disease has a wide range of signs, symptoms, and manifestations. 
However, subclinical infections have been shown to occur through seroprevalence 
studies done in endemic regions (49). It is important to note that the human immune 
response to early infection by one strain of Lyme Borrelia is non-protective against other 
strains, resulting in reinfection (59, 86, 88, 122). The “hallmark” sign of early invasion is 
the erythema migrans rash, but only occurs in 60-85% of patients (85, 124). Other 
symptoms of acute infection can include fatigue, myalgia, arthralgia, headache, fever, 
and chills (85). However, an early diagnosis and subsequent treatment with oral 
antibiotics such as doxycycline or amoxicillin has proven very effective in the treatment 
of Lyme disease (125). 
Due to non-specific signs of early infection, Lyme borreliosis is often allowed to 
progress untreated for long periods, which can lead to more serious sequelae. Later 
manifestations can include Lyme arthritis, neurological conditions such as 
6
Figure 1-3. 2011 case distribution of  Lyme disease in the United States. A map of 
the location of confirmed cases of Lyme disease in the United States that occured in 
2011. Each dot represents a single case randomly placed in the county of residence. 
The endemic region of Lyme disease primarily lies in the Mid-Atlantic, Northeast, and 
upper Midwest.
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Table 1-1. Case numbers and incidence rates in the United States per state. 
State Confirmed Probable Incidence* 
Alabama 9 15 0.2 
Alaska 9 2 1.2 
Arizona 8 7 0.1 
Arkansas 0 0 0 
California 79 13 0.2 
Colorado 0 0 0 
Connecticut 2004 1035 56 
Delaware 767 106 84.6 
DC N N N 
Florida 78 37 0.4 
Georgia 32 0 0.3 
Hawaii 0 0 0 
Idaho 3 1 0.2 
Illinois 194 0 1.5 
Indiana 81 13 1.2 
Iowa 72 28 2.4 
Kansas 11 6 0.4 
Kentucky 3 0 0.1 
Louisiana 1 1 0 
Maine 801 205 60.3 
Maryland 938 413 16.1 
Massachusetts 1801 675 27.3 
Michigan 89 15 0.9 
Minnesota 1185 939 22.2 
Mississippi 3 2 0.1 
Missouri 5 3 0.1 
Montana 9 2 0.9 
Nebraska 7 4 0.4 
Nevada 3 2 0.1 
New Hampshire 887 412 67.3 
New Jersey 3398 864 38.5 
New Mexico 2 4 0.1 
New York 3118 1372 16 
North Carolina 18 70 0.2 
North Dakota 22 5 3.2 
Ohio 36 17 0.3 
Oklahoma 2 0 0.1 
Oregon 9 29 0.2 
Pennsylvania 4739 623 37.2 
Rhode Island 111 48 10.6 
South Carolina 24 13 0.5 
South Dakota 2 2 0.2 
Tennessee 5 32 0.1 
Texas 28 46 0.1 
Utah 6 3 0.2 
Vermont 476 147 76 
Virginia 756 267 9.3 
Washington 17 2 0.2 
West Virginia 107 11 5.8 
Wisconsin 2408 1241 42.2 
Wyoming 1 1 0.2 
U.S. TOTAL 24,364 8,733 7.8 
*per 100,000 population 
 
Table adapted from the 2012 CDC report 
(http://www.cdc.gov/lyme/stats/chartstables/reportedcases_statelocality.html) 
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neuroborreliosis, cutaneous disorders, and cardiac abnormalities such as endocarditis 
(7, 51, 60, 129, 139). Beyond the potential for debilitating medical conditions, the 
financial burden of Lyme disease in the United States is severe. A study was done 
calculating the approximate cost per case; this came to approximately $8200 in a 2006 
study (146). Despite the substantial financial burden that Lyme disease imposes, 
prevention is restricted to avoidance of exposure to high-risk environments and early 
recognition of acute symptoms.  As the causative agent of Lyme disease in the United 
States, B. burgdorferi is a prominent pathogen with fascinating survival mechanisms in 
hosts spanning multiple phyla.  
B. burgdorferi is a bacterial species that must survive by efficiently transmitting 
between two highly dissimilar host environments in a process known as the enzootic 
cycle. As a tick-borne pathogen, the bacteria are spread by the deer tick (I. scapularis), 
which has a two year life cycle depicted in Figure 1-4 (102). Eggs are laid in early spring 
and hatch in the summer (102). The larval tick that emerges is uninfected since B. 
burgdorferi are incapable of transovarial transmission (102). In late summer and early 
fall, the larvae feed on one of a plethora of mammalian, avian, and reptilian hosts (102). 
Transmission of B. burgdorferi to the tick vector often occurs at this stage by feeding on 
an infected member of the small mammal reservoir, commonly the white-footed mouse 
(102). The larvae then molt into the nymphal stage and lay dormant through the winter, 
through this time the bacteria remain in the mid-gut (102). These nymphal ticks take 
their second blood-meal in the spring or summer (102). It is this blood meal that causes 
the spirochetes to migrate into the salivary glands and effectively transmit to this 
secondary host, resulting in infection (73, 126). In the fall, nymphs moult into adults 
9
Figure 1-4. Enzootic cycle of the Lyme disease spirochete. The B. burgdorferi 
vector is primarily the I. scapularis tick, which has a complex, multi-stage life cycle. The 
cycle begins with eggs hatching in the summer. The larvae ticks that emerge are free of 
Borrelia. In the summer and fall, the ticks feed on their first host, which range widely in 
variety and include squirrels, mice, and birds.  It is from this blood-meal that the ticks 
often obtain the bacteria. The fed tick drops off the host and remains dormant through 
the winter, moulting into the nymph life stage. The tick then feeds on a second host in the 
spring or summer and this is where transmission of the Lyme spirochete occurs. 
Infection of small mammal and avian hosts results in the continuity of the enzootic cycle. 
Fed nymphs drop off and moult into the adult stage. Adults feed and procreate on large 
mammals such as deer in the fall and winter, after which the adult females lay eggs in the 
spring. These eggs are uninfected since B. burgdorferi cannot transmit to the ova of the 
tick. It is significant to note that humans and canines are able to be infected, but they are 
dead-end hosts and do not contribute to the perpetuation of the bacteria in the 
environment. A hallmark symptom of human infection by B. burgdorferi is a “bulls-eye” 
or erythema migrans rash.
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(102). It is in this stage that the ticks feed and copulate on large mammals such as deer 
through the fall and spring (102). Deer are incompetent hosts for B. burgdorferi, but 
facilitate the spread of the disease by traversing great distances and expanding the 
range of potential hosts (102). In the spring, the enzootic cycle ends with the adult 
female laying eggs and dying (102). It is significant to note that while humans and dogs 
are capable of being infected, they are usually dead-end hosts and do not contribute to 
the perpetuation of the bacteria in the environment. 
Because B. burgdorferi must survive within two disparate host environments, 
drastic transcriptional and translational changes must occur to effectively transmit and 
avoid each host’s defenses (50, 121). Despite the necessity for rapid, global 
transcriptional changes, the B. burgdorferi genome contains very few transcriptional 
regulators. For example, only three sigma factors (RpoD, RpoN, and RpoS) have been 
identified in the B. burgdorferi genome (52). RpoD (σ70) is the general, house-keeping 
sigma factor.  RpoN (σ54) has been shown to transcribe multiple genes including RpoS, 
the other alternate sigma factor (26, 66).  RpoS (σ38/ σs) aids in transcription of host-
specific factors such as OspC, an outer surface protein only expressed in early 
mammalian infection (66).  Synthesis of RpoS has multiple regulatory elements. Rrp2 (a 
two-component response regulator) is a σ54 enhancer-binding protein that requires 
phosphorylation to activate the transcription of rpoS (144). BosR is a DNA binding 
protein shown to directly interact with the rpoS promoter and allow transcription (91).  
Along with transcriptional regulation, RpoS synthesis is also temperature-regulated at 
the translational level by a small RNA, DsrA, which is stabilized by the RNA chaperone 
Hfq (76, 77).  
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Regulatory elements are often suppressed or induced by environmental stimuli. 
A method that bacteria use to detect those stimuli is two-component systems. Most 
bacteria have many two-component regulatory systems, such as Escherichia coli with 
30 to 60 (52).  However, B. burgdorferi encodes five, only two of which are capable of 
global regulation (84, 144). These are Rrp1-Hpk1 and Rrp2-Hpk2 (107, 144). The Rrp2-
Hpk2 system has been implicated in rpoS transcriptional regulation that initiates survival 
mechanisms specific to the mammalian host. Response regulators often contain DNA-
binding domains, including Rrp2 (144). However, Rrp1 lacks a DNA-binding domain, but 
instead has a GGDEF domain and will be expounded upon later in this thesis (107, 
116). As in other two-component systems, activation of the response regulator, Rrp1, 
requires phosphorylation by the cytoplasmic membrane-embedded histidine kinase, 
Hpk1 (32, 62, 116). In this manner, the sensory protein detects an external stimulus to 
initiate downstream functions and regulate cell activity (142). The scarcity of broad-
spectrum regulatory pathways correlates with the overall minimization of the B. 
burgdorferi genome. 
Small, fragmented, and condensed, the B. burgdorferi genome is comprised of a 
0.91 Mb linear chromosome as well as a cohort of linear and circular plasmids that 
varies from strain to strain; the type strain B31 has 12 linear and 9 circular plasmids 
(105). The collective coding sequences of the chromosome occupy 93% of the genetic 
material with a great deal of gene overlap (52). This compacted chromosome expresses 
most of the housekeeping genes while others, many vital to bacterial survival in hosts, 
are expressed off of the bacterium’s arsenal of plasmids (e.g. OspC from cp26, 102). 
Despite its genetic dwarfism, B. burgdorferi has retained 54 chemotactic/motility genes; 
12
this correlates with approximately 6% of the genome (52). This large percentage and 
the fact that non-motile B. burgdorferi are non-infectious exemplify the importance of 
motility for B. burgdorferi survival (74). 
 
Tick-borne relapsing fever 
 Unlike the more recently discovered Lyme disease, relapsing fever has far more 
ancient roots in human history. Since the days of Hippocrates, a disease was described 
similar to what is known as relapsing fever today (41). Louse-borne relapsing fever 
(caused by B. recurrentis) is likely correlated with the yellow plague of Europe in 550 
A.D. and was responsible for millions of cases during World War I and II (111). Tick-
borne relapsing fever (TBRF) occurs throughout the world with the highest incidence 
rates in Africa (47). Unfortunately, most African countries do not have a reporting 
system for TBRF, so the actual infection rates of this disease are difficult to discern (78). 
However, infection studies in smaller populations have been conducted and provide 
insight into the severity of impact that TBRF can have. 
The soft-bodied Ornithodoros tick is the vector for TBRF. Unlike the Lyme 
disease species, the TBRF spirochetes can use their vector as a reservoir species due 
to transovarial transmission and long-term survival (47, 123). Ornithodoros ticks live in 
protected niches of caves, mud-huts, trees, and cabins where small mammals frequent 
(118). Unlike the Ixodes, Ornithodoros ticks can live for many years and adult females 
reproduce after every blood-meal of that lifespan (8, 47, 79). Because of the life cycle 
and span of its tick vector, there are high percentages of TBRF-infected ticks in the 
environment (8, 41, 118). 
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Like Lyme disease, the endemic regions of TBRF are highly specific to the 
habitat and distribution of the vector species (93). For example, in the United States, 
50% of TBRF cases have occurred in only 13 counties and this distribution is shown in 
Figure 1-5 (47). This endemic region correlates with the presence of the most common 
cause, B. hermsii and its vector, O. hermsi (45).  
Another factor in TBRF epidemiology is the living conditions of the human 
population. For example, many African communities live in mud-huts, which are an ideal 
location for ticks to reside and feed on the human inhabitants at night (43, 92).  Studies 
in Senegal revealed TBRF as the most common bacterial infection and the Tanzanian 
town of Mvumi reported TBRF to be the 7th highest cause of death in children with a 
perinatal mortality rate of 436 per 1000 cases (42, 78, 136, 140). While cases in the 
United States are generally unsuspecting cabin vacationers, TBRF is a global health 
concern with severe medical outcomes.  
Disease progression of TBRF begins with exposure to the bacteria through a 
tick’s blood-meal that can last from a fifteen minutes to two hours (47, 79, 92). These 
blood-meals are brief, nocturnal, and painless, primarily occurring while the human host 
is asleep (47, 140). The transmission of the bacteria from the tick vector to the 
mammalian host is rapid and may take as little as 30 seconds, while B. burgdorferi 
transmission requires 24 to 48 hours (47). After infection, there is an incubation period 
that lasts for several days before disease signs and symptoms begin (47).These are 
variable and can include headache, myalgia, nausea, arthralgia, and/or abdominal 
complaints (47). Some less transient manifestations include neuroborreliosis, 
splenomegaly, and myocarditis (4, 31, 141). However, the most common and name-
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Figure 1-5. Tick-borne relapsing fever incidence in the United States. Above is the 
distribution of TBRF cases in North America. Highlighted are the counties in which 
TBRF patients had been diagnosed up to 2002.
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sake symptom is a recurring, severe fever, often near or surpassing 104oF (45, 123). 
These febrile periods correlate with high levels of blood spirochetemia (47, 92). The first 
febrile period lasts an average of three days with approximately a week between the 
end of the initial febrile period and the start of the first relapse (47). As many as 13 
relapses have been documented with spirochetemia reaching from 106 to 108 bacteria 
per mL of blood (42, 45). This clinical outcome is due to afebrile period sequestration of 
the bacteria in the internal organs and then reemergence resulting in the fever symptom 
(93). The molecular mechanism by which B. hermsii causes this recurring fever is 
through antigenic variation (14).  
B. hermsii has been shown to have as many as 40 different serotypes that can 
be generated from a single spirochete (105). This is possible through several 
mechanisms of genetic recombination that result in one of many silent variable major 
protein (vmp) genes translocating to the downstream region of the appropriate 
promoter, allowing transcription (12, 106). It is with the expression of a new Vmp that 
the dominant serotype of the B. hermsii population changes, leading to immune evasion 
and increased spirochetemia (105).  
Antigenic variation and other elaborate mammalian host-specific immune evasion 
mechanisms are often associated with efficient signal transduction systems to alter the 
B. hermsii transcriptome upon host invasion. While this species is not quite as 
dependent on its mammalian host for survival as the Lyme disease spirochetes, B. 
hermsii regularly infects small mammals such as tree squirrels, chipmunks, and ground 
squirrels (46). Therefore, this species must also harbor mechanisms of global 
transcriptional regulation specific to the tick-mammal and mammal-tick transmission. 
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 Cyclic di-GMP 
Borrelia undergo rapid, drastic changes in gene expression and biochemical 
processes that require efficient signal transduction systems. Bis-(3'-5')-cyclic dimeric 
guanosine monophosphate (c-di-GMP) is a recently discovered bacterial secondary 
signaling molecule originally shown to regulate cellulose synthesis in Gluconacetobacter 
xylinus (110). Since then, it has been implicated in the regulation of many pathways 
among a plethora of bacterial species (5, 9, 67, 116).  
All second messenger molecules function to relay signals, altering downstream 
cellular processes. These messengers are often small, making them energy efficient 
and capable of rapid diffusion throughout the cytoplasm. Structurally, c-di-GMP 
comprises two GMP molecules connected by two phosphodiester linkages and is 
depicted in Figure 1-6. These linkages result in a rigid, twelve-member ring, but 
flexibility in the glycosidic bonds between the ribose sugars and guanine bases allows 
for c-di-GMP to exist in two primary conformations (53, 117). The open conformation is 
depicted in Figure 1-7a, and the closed in Figure 1-7b. This difference in the glycosyl 
torsion angle is seen in other cyclic di-nucleotides, such as cyclic dimeric adenosine 
monophosphate (53). It is also significant to note that two monomers of c-di-GMP in the 
closed conformation are capable of associating due to base pair stacking. This results in 
an intercalated dimer, shown in Figure 1-7b (20, 48). C-di-GMP is capable of higher 
orders of oligomerization although it primarily exists in the monomer or dimer form at 
physiologically relevant concentrations (48, 117). 
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Figure 1-6. Cyclic di-GMP structure.  Two GTP molecules are circularized by a 
diguanylate cyclase to form c-di-GMP. Two phosphodiester bonds generate a twelve 
member ring out of the ribose sugars and phosphate groups. 
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Figure 1-7. Cyclic di-GMP conformations allow for multimerization. The flexibility 
of the glycosidic bond between the ribose sugar and the guanine base allows for two 
primary conformations. The open conformation is shown in panel A while the closed 
conformation can be seen in panel B. In the closed conformation, two c-di-GMP 
molecules can also intercalate through base pair stacking of the guanines as well as 
hydrogen bond formation between the phosphate group of one molecule and the 
guanine base of the other.
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Synthesis of c-di-GMP from two guanosine triphosphate (GTP) molecules is 
carried out by a group of proteins known as diguanylate cyclases (DGCs), which are 
typified by a GGDEF protein domain (9, 35, 63, 96, 135). It is at a conserved loop-
forming motif (formed by the GGDEF sequence) where binding of the two GTPs occurs 
at a dimeric interface between two domains (95, 97). The GGDEF motif associates with 
one molecule of GTP by interacting with the phosphates as well as the guanine base 
and contributes to the high degree of binding specificity of these proteins (35). 
Breakdown is carried out by phosphodiesterases (PDEs), of which there are two 
groups. Some contain an EAL motif and these hydrolyze only one of the phosphodiester 
bonds of c-di-GMP, forming a pGpG molecule (21). Others contain an HD-GYP domain 
and catabolize c-di-GMP into its two GMP constituents (38, 57, 58, 114). It is through 
the activity of DGCs and PDEs that c-di-GMP levels and downstream effects are 
modulated within the cell. 
C-di-GMP signaling regulates a variety of cellular functions among many 
bacterial species. As a matter of fact, c-di-GMP-metabolizing proteins have been 
discovered in most major phyla (109). The first discovered function of c-di-GMP was 
activation of exopolysaccharide biosynthesis in the form of cellulose production in G. 
xylinus (110). This has since expanded to include others, such as alginate production in 
Pseudomonas aeruginosa (81, 82). Other common regulatory functions of c-di-GMP 
include cell cycle progression, virulence factor production, and long-term persistence 
(23, 72, 80, 96, 138). However, perhaps the most defined functions of c-di-GMP are 
biofilm formation and motility (82). As a bacterial process known to confer properties 
that increase pathogenicity, biofilm formation has been a major area of focus in c-di-
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GMP research (108).  Among multiple species, including prominent pathogens such as 
Yersinia pestis, Vibrio cholerae, Salmonella enterica, and P. aeruginosa, increased 
levels of c-di-GMP induce biofilm formation while decreased levels result in an increase 
in planktonic cells and motility (22, 23, 40, 120, 137). These phenotypes are exhibited 
through c-di-GMP-induced regulation of gene expression and protein activity (37, 115, 
143).  
Cellular functions modulated by c-di-GMP can be altered at multiple stages within 
the biochemical pathways, including transcription, translation, and post-translational 
modifications (109). The transcription of messenger ribonucleic acid (mRNA) can be 
regulated by binding of transcription factors, enhancers, or suppressors (109). In this 
way, gene expression may be upregulated or downregulated depending on intracellular 
c-di-GMP levels (109). Once the target genes are transcribed, translational regulation 
can be carried out by c-di-GMP-activated proteins or riboswitches, which are secondary 
structures within mRNA that can directly bind c-di-GMP to promote or inhibit translation 
(109). Lastly, c-di-GMP can regulate protein levels and functionality through proteolysis, 
activation, or deactivation (44).  
C-di-GMP-mediated regulation is highly reliant on the receptors/effectors to 
which this second messenger binds. Known receptors come in many forms and carry 
out an array of functions. Two types of riboswitches have been discovered to bind c-di-
GMP and are present in many species, often with multiple incidences within a single 
genome (109). Other receptors can include degenerative GGDEF, EAL, or HD-GYP 
domain proteins that have lost their catalytic activity, but are still capable of binding c-di-
GMP (109). The last group of common receptors contains a highly conserved domain 
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known as the PilZ domain (6). This domain confers c-di-GMP binding with a moderate 
to high affinity (6). Other receptors are less predictable and therefore difficult to find, but 
are gradually being discovered.  
The PilZ domain was first discovered by bioinformatics analyses and postulated to 
bind c-di-GMP, which was quickly confirmed experimentally and named after the P. 
aeruginosa PilZ protein (3, 6, 115). These studies and more have shown that several 
residues are highly conserved and these form an RxxxR/DzSxxG motif where x 
represents any amino acid and z represents a hydrophobic amino acid. Crystallography 
and nuclear magnetic resonance studies have shown that these residues do, indeed, 
interact with c-di-GMP and that it can be in the monomeric or intercalated dimer 
conformation (15, 61, 69, 103, 119). While PilZ domain-containing proteins have been 
implicated in the regulation of many cellular processes, the best characterized have 
been shown to regulate motility. 
PilZ protein-mediated regulation of motility can act through methods such as 
expression of motility genes or protein-protein interactions. An example of PilZ protein-
regulated gene expression is Klebsiella pneumoniae’s MrkH (143). This transcription 
factor binds the promotor of a type III fimbriae gene cluster to facilitate biofilm formation 
in the presence of c-di-GMP (143). More commonly, however, PilZ proteins have been 
shown to interact with other proteins to alter function. The S.ernterica serovar 
Typhimurium PilZ protein, YcgR, is the most thoroughly described c-di-GMP binding 
protein (115). It interacts with c-di-GMP to associate with the flagellar motor complex 
and inhibit motility (94, 115). PilZ domain proteins are an important part of a bacterium’s 
c-di-GMP regulatory network. The fact that almost every genome with a diguanylate 
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cyclase, including both B. burgdorferi and B. hermsii, also contains at least one PilZ 
domain protein lends evidence to that fact (109). 
 
C-di-GMP signaling in the Borrelia 
 GGDEF, EAL, HD-GYP, and PilZ domain containing proteins have been found in 
the genomes of most spirochete species, indicating the presence of c-di-GMP signaling 
systems (109). However, the surface of c-di-GMP functionality within the Spirochaete 
phylum has barely been scratched. B. burgdorferi and B. hermsii are particularly unique 
in that they each harbor only one diguanylate cyclase and two phosphodiesterases. 
Other species, such as P. aeruginosa have as many as 41 c-di-GMP metabolizing 
proteins (109). The simplicity and genetic malleability of these bacteria make them 
appealing systems in which to study c-di-GMP signaling.  
 The B. burgdorferi c-di-GMP network is slowly being unraveled. However, the B. 
hermsii system has largely been left untouched. A sequence comparison of the B. 
burgdorferi B31 and the B. hermsii DAH c-di-GMP-associated proteins reveals the high 
degree of homology between these two systems and can be found in Figure 1-8. The 
sequence identities of these proteins range from 65 to 76% and the sequence 
similarities from 82 to 89%. The BB0419 and BH0419 are the sole diguanylate cyclases 
in the respective species (Rrp1, 71, 107, 133). BB0363 and BH0363 refer to the EAL 
domain containing phosphodiesterases (PdeA, 107, 132). BB0374 and BH0374 are the 
HD-GYP phosphodiesterases (PdeB, 107, 131). BB0733 is the only known PilZ domain 
containing protein of B. burgdorferi (PlzA) and BH0733 is the B. hermsii counterpart 
(PlzC, 55, 98). Deletion mutants have been generated in each of the B. burgdorferi 
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Figure 1-8. Sequence homology between the B. burgdorferi and B. hermsii c-di-GMP 
metabolizing proteins. Each sequence alignment was generated in ClustalW. The 
asterisk (*) labels identical residues between the B. burgdorferi and B. hermsii species. The 
colon (:) labels residues with charge similarity. The period (.) labels residues with structural 
similarity. The BB0419 and BH0419 had 76% identity and 89% similarity. The GGDEF is 
highlighted. BB0363 and BH0363 had 69% identity and 84% similarity. The EAL domain is 
highlighted.  BB0374 and BH0374 had 65% identity and 84% similarity. The HD-GYP 
domain is highlighted.  BB0733 and BH0733 had 69% identity and 82% similarity. The PilZ 
domain motifs are highlighted.
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genes listed above and their phenotypes described (55, 71, 98, 107, 131, 132, 133). A 
schematic of the B. burgdorferi c-di-GMP binding system can be found in Figure 1-9. 
 Interference in the c-di-GMP signaling system of the Borrelia results in multiple 
phenotypes. Deletion of the sole diguanylate cyclase gene, rrp1, resulted in an inability 
to colonize ticks (62, 71, 133). A deletion mutant of hpk1 had a very similar phenotype 
because the diguanylate cyclase activity of Rrp1 is dependent on phosphorylation by 
Hpk1 (32, 62, 116). Alternatively, deletion of one of the phosphodiesterase genes 
(pdeA) abolished mouse infectivity, but retained tick colonization comparable to wild-
type (132). However, deletion of the other phosphodiesterase (pdeB) resulted in normal 
murine infectivity and reduced, but not abolished tick survival (131). Lastly, a deletion of 
the only c-di-GMP binding molecule found in B. burgdorferi, plzA, led to reduced 
invasion of both the mouse and tick host (98). Most of these mutants also had 
alterations in motility and chemotaxis (71, 98, 131, 132, 133). The only consistent 
phenotype in all mutants was an inability to transfer between the mammalian host and 
tick vector to complete the enzootic cycle, which is paramount for the perpetuation of B. 
burgdorferi in the environment.  
 
Research objectives 
 PlzA is the only confirmed c-di-GMP binding molecule produced by B. burgdorferi 
(55). As such, it is the only possible known c-di-GMP effector. Therefore, 
characterization of PlzA activity and its interaction with c-di-GMP could elucidate the 
molecular mechanisms of c-di-GMP regulation in B. burgdorferi. 
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Figure 1-9. Schematic of the c-di-GMP network of B. burgdorferi. The B. burgdorferi  
c-di-GMP network has been characterized as to enzymatic activity if not downstream 
functionality. Hpk1 is embedded in the cytoplasmic membrane and theoretically detects 
an external stimuli to induce autophosphorylation of histidine residues. This, in turn, 
activates the diguanylate cyclase Rrp1 to synthesize c-di-GMP from two GTP 
molecules. Degredation of c-di-GMP is carried out by PdeA through linearization of the 
secondary messenger into the pGpG form or by PdeB which breaks it down into two 
GMP molecules. The last B. burgdorferi c-di-GMP interacting protein is PlzA, which 
contains a functional PilZ domain that confers c-di-GMP binding.
PdeA
PdeB
PlzA
Cytoplasmic Membrane
Rrp1
Hpk1
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 Due to its sequence homology to PlzA, the study of the B. hermsii PilZ domain 
protein, PlzC, would be very appealing as one of the first steps in delineating the c-di-
GMP regulatory network of the TBRF spirochete. While nothing has been published on 
c-di-GMP signaling in the relapsing fever bacterium, preliminary data from our lab 
implies that c-di-GMP signaling has an effect on the motility, chemotaxis, and disease of 
B. hermsii (54). Unfortunately, altered phenotypes in enzootic cycle progression cannot 
be assessed at this time since there are no uninfected O. hermsi ticks commercially 
available. 
 Through biochemical and biophysical methods such as amino acid substitution, 
fluorescence resonance energy transfer, isothermal titration calorimetry, and size 
exclusion chromatography, our lab has shed light on the c-di-GMP interaction with the 
only PilZ domain containing proteins of B. burgdorferi and B. hermsii, PlzA and PlzC 
respectively. 
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Chapter 2: Materials and Methods 
 
Borrelia strains and cultivation 
 B. burgdorferi B31-5A4 cells were cultivated in Barbour-Stoenner-Kelly (BSK-H) 
media supplemented with 6% rabbit serum (10). B. hermsii DAH cells were cultivated in 
BSK-H media supplemented with 12% rabbit serum. All strains were maintained under 
humidified conditions with 5% CO2 and at 25, 33, or 37oC. These isolates are listed in 
Table 2-1.  
 
Plasmid construction    
 Strains and plasmids used in this study are listed in Table 2-1.  All fluorescent 
resonance energy transfer (FRET) expression plasmids were derived from pFRET12AA 
plasmid (89). The construct constitutes a flanking fluorescence resonance energy 
transfer (FRET) pair (YFP and CFP) on either side of a multiple cloning site and 
encodes twelve amino acids.  The mYPet (YFP) and mCyPet (CFP) genes contain 
mutations that prevent oligomerization that could interfere with signal.  A positive control 
FRET construct, MC0118 (kindly provided by Dr. Samuel Miller) contains the 
Salmonella enterica serovar Typhimurium gene encoding the PilZ domain protein YcgR 
and exhibits a characterized conformational change upon binding of c-di-GMP using 
FRET [Christen, 2010 #2452].  A SpeI site was introduced at the 5' end and a KpnI site 
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Table 2-1. Strains and plasmids used in this study. 
Strain or Plasmid Description Source 
E. coli NovaBlue   
E. coli BL21 (DE3)   
B. hermsii DAH   
B. burgdorferi B31   
pFRET12aa pET15b::mYPet_12AA_mCyPet (89) 
MC0118 pET15b::mYPet_ycgR_mCyPet (39) 
pFRETplzC pET15b::mYPet_plzC_mCyPet this work 
pFRETplzA pET15b::mYPet_plzA_mCyPet this work 
pFRETplzAR145D pET15b::mYPet_plzAR145D_mCyPet this work 
pFRETplzAR145K pET15b::mYPet_plzAR145K_mCyPet this work 
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at the 3' end of all PCR products.  plzA (BB0733) was amplified from genomic DNA of 
the B. burgdorferi strain B31.  plzC (BH0733) was amplified from the DAH strain of B. 
hermsii.  Using splice overlap exchange techniques, the plzA arginine residue at 
position 145 was substituted with an aspartic acid (AGA to GAT) and a lysine (AGA to 
AAA). All primers used in this study can be found in Table 2-2.  Upon sequence 
confirmation of each construct, the plasmids were transformed into BL21 (DE3) cells.  
Schematics of the pFRETplzA plasmid and the pFRETplzC plasmid can be found in 
Figure 2-1. 
 For the purpose of His-tagging PlzA, PlzAR145D, PlzAR145K, and PlzC, plzA 
was PCR amplified from B31 gDNA and plzC from DAH gDNA. plzAR145D and 
plzAR145K were amplified from their respective FRET constructs using the plzA specific 
primers. PCR products were then inserted into pET45b(+, Novagen) using restriction 
sites indicated by the primer name in Table 2-2. Plasmids were sequence verified and 
transformed into BL21 (DE3) cells for protein expression. 
 
Protein expression and purification.   
 All proteins in the study were expressed in Lysogeny Broth supplemented with 
100 µg/mL ampicillin.  Cultures of the transformed BL21 (DE3) cells were grown to log 
phase at 37C then chilled on ice for 15 min. Protein expression was induced with 
isopropyl ß-D-1-thiogalactopyranoside (IPTG). FRET proteins were induced with IPTG 
at a 20 µM concentration for 24 hours at 18C. His-tagged proteins were induced with 
IPTG at a concentration of 200 µM for 18 hours at room temperature.  Cells were 
recovered by centrifugation then lysed with lysozyme (1 mg/mL) and sonication.  
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Table 2-2. Oligonucleotides used in this study. 
Primer name Primer sequence 
PlzA Spe I 5' F ATAGTGACTAGTATGCTTTTATCTAGAAAAATAAGAGATTATGGGGCTAAGTATAGG 
PlzA Kpn I 3' R ATAGTGGGTACCATTGAAATAATCATGGATCAACATAGTATACTCAAGTGGTATTTTATC 
PlzA R145D SOE 5' F GGGCAAAATCAGGATATTCATGAGAGGATTATTATCGATAAAGATTCTATTAGAAAGC 
PlzA R145D SOE 3' R CCTCTCATGAATATCCTGATTTTGCCCAAGCTTTAAATCAAGAAGC 
PlzA R145K SOE 5' F GGGCAAAATCAGAAAATTCATGAGAGGATTATTATCGATAAAGATTCTATTAGAAAGC 
PlzA R145K SOE 3' R CCTCTCATGAATTTTCTGATTTTGCCCAAGCTTTAAATCAAGAAGC 
PlzC Spe I 5' F ATAGTGACTAGTATGTTTTTGTCTCGAAAAATAAAAGATTATGAAGTTAAGTATAAGG 
PlzC Kpn I 3' R ATAGTGGGTACCATTAAAATAATCATGGATTAACATAGTATAAGCAAGGGGAATC 
PlzA Age I 5' F ATAGTCACCGGTCTTTTATCTAGAAAAATAAGAGATTATGG 
PlzA Xho I 3' R CTATCACTCGAGTTAATTGAAATAATCATGGATCAACATAGTATACTC 
PlzC Xho I 5' F TATCACCTCGAGATGTTTTTGTCTCGAAAAATAAAAGATTATGAAGTTAAGTATAAGG 
PlzC Xho I 3' R TATCACTTAATTAAAATAATCATGGATTAACATAGTATAAGCAAGGGGAATC 
    
 
31
Figure 2-1. Schematic of FRET constructs and recombinant proteins. Panel A is a 
depiction of the FRET protein expression plasmids used in this study. The left was used 
for expression of YFP-PlzA-CFP, YFP-PlzAR145D-CFP, and YFP-PlzAR145K-CFP. The right 
was used for expression of YFP-PlzC-CFP. Panel B is a depiction of all of the FRET 
proteins used in this study, including the YFP-CFP negative control and the YFP-YcgR-
CFP positive control.
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Soluble proteins were isolated by high speed centrifugation and purified using Ni-NTA 
affinity chromatography with His-trap columns (GE Healthcare) on an AKTA purification 
system (GE Healthcare).  The FRET proteins were dialyzed into PBS and the His-
tagged proteins into a buffer containing 150 mM NaCl and 10 mM Tris (pH 8.0) using 
Spectra/Por dialysis membranes (Spectrum Laboratories).  Proteins were quantified 
using a bicinchoninic acid protein assay kit (Pierce) or 280 nm wavelength absorption, 
then visualized via Coomasie-stained sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (BioRad) to assess purity.  
 
FRET analysis 
 Assays were performed using a PHERAstar FS microplate reader (BMG) with a 
YPET CYPET 425 480 530 filter.  Excitation was induced with a light wavelength of 425 
nm and fluorescence intensity was detected at 480 nm (CFP emission) and 530 nm 
(YFP emission).  Fluorescence intensity was measured every 0.2 seconds at each 
wavelength over 30 seconds.  Recombinant FRET proteins (500 nM) were assayed in 
triplicate in low volume 384-well black plates (ProxiPlate).  5 µL of c-di-GMP (Biolog) 
was injected at the 5 second time point for a final concentration of 25 µM in 25 µL.   
 
Size exclusion chromatography 
 His-tagged PlzA and PlzC (40 µM) were incubated with and without c-di-GMP (40 
µM) in 550 µL of a buffer containing 150 mM NaCl and 10 mM Tris (pH 8.0) on ice for 1 
hour. A control of c-di-GMP alone was also incubated. 500 µL of each reaction was 
separated on a Superdex-75 column (GE Healthcare) using an AKTA purification 
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system (GE Healthcare) and elution monitored at 280 nm. 250 µL fractions were 
collected for later analyses.  
 
Reverse phase chromatography 
 Three of the protein and c-di-GMP elution fractions were consolidated into 750 µL 
samples. These samples were boiled for 10 min to denature the protein, then 
centrifuged at 14,000 rpm for 15 min to remove the precipitated protein. The aqueous 
portions were filtered using Amicon Ultracel filters with a molecular weight cut off of 3 
kDa (Millipore). 500 µL of each sample was injected into the 15 x 4.6 cm Supelcosil LC-
18-T column (Supelco) using an AKTA purification system (GE healthcare). The reverse 
phase gradient program used a buffer on line A containing 100 mM KH2PO4 and 4 mM 
tetrabutyl ammonium hydrogen sulfate (pH 5.9) and the buffer on line B was 75% buffer 
A and 25% methanol. The step gradient ran at a flow rate of 0.5 mL min-1 for 18 mL. The 
program is as follows with the time point and percentage of buffer B: 0 min, 0%; 7.0 min, 
30%; 14.0 min, 60%; 19.6 min, 100%; 30.8 min, 50%; and 32.2 min, 0%. Absorbance 
was measured at the 254 nm wavelength for the detection of nucleic acids. 
 
Isothermal titration calorimetry 
  ITC was performed using a VP-ITC microcalorimeter (MicroCal) at 25C. His-
tagged proteins and c-di-GMP were suspended in a buffer containing 150 mM NaCl and 
10 mM Tris-HCl (pH 8.0). PlzA and the two substitution mutant proteins were assayed 
at a concentration of 50 µM in the cell with 1 mM c-di-GMP titrating in the cell from the 
syringe. 20 µM of PlzC was assayed in the cell with 0.2 mM c-di-GMP in the syringe. 
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For all reactions, the initial c-di-GMP injection was a 0.5 µL volume over a duration of 1 
s with a spacing of 120 s. 23 more injections of 1.5 µL followed for a 3 s duration and 
120 s spacing. Data was analyzed using Origin software assuming a single binding site 
(MicroCal). 
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Chapter 3: Results 
 
Recombinant protein purity 
 FRET recombinant proteins (YFP-YcgR-CFP, YFP-PlzC-CFP, YFP-PlzA-CFP, 
and subsequent PlzA mutants) were shown at the expected size of ~85 kDa while the 
negative control (YFP-CFP) migrated at a molecular weight of 58 kDa (Figure 3-1a). 
His-tagged PlzA, PlzAR145D, and PlzAR145K migrated to the expected molecular weight of 
30 kDa and PlzC, to 35 kDa (Figure 3-1b). 
 
PlzA and PlzC undergo a FRET-detectable conformational change when c-di-GMP 
binds 
 FRET is a technique that utilizes fluorophores that share the same wavelength 
range of emission by a donor and excitation by an acceptor. Therefore, the relative 
proximity of a donor to an acceptor molecule can be measured based on the amount of 
transference. If a FRET pair flanks a ligand receptor that exhibits a conformational 
change upon ligand binding, the changes in the distance and/or orientation of the two 
fluorophores due to ligand binding can be detected through fluctuations in the emission 
ratio. The specifics of this technique can be seen in Figure 3-2.  
 In vitro kinetics of the YFP-PlzA-CFP and YFP-PlzC-CFP proteins displayed a 
change in the emission ratio (480 nm/530 nm) upon addition of c-di-GMP that is 
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Figure 3-1. SDS-PAGE of recombinant proteins purified in this study. 1 
Panel A consists of the His-tagged FRET recombinant 
proteins. Panel B consists of the His-tagged recombinant proteins. All proteins migrated to 
the expected molecular weight, shown by the ladder and arrows on the left.
µg of purified 
recombinant protein was run on a 15% Tris-HCl polyacrylamide gel. The gel was stained 
with Coomasie Brilliant Blue. 
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Figure 3-2. Fluorescence resonance energy transfer for conformational change 
detection. 
 
CFP is excited by a laser beam with a wavelength of 425 nm , which can in turn 
excite YFP with a 480 nm emission, which results in a secondary emission at 530 nm. The 
efficiency of this energy transfer is dependent on the distance between these two 
fluorophores. Therefore, the relative proximity/orientation of the YFP and CFP can be 
measured based on the energy transfer between them. By introducing a spacer protein 
between the FRET pair, a structural rearrangement due to ligand binding can be detected 
by a change in the emission ratio of YFP and CFP.
425 nm 425 nm
480 nm 480 nm
530 nm 530 nm
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depicted in Figure 3-3. This is indicative of a c-di-GMP-induced conformational change 
in PlzA and PlzC. YFP-YcgR-CFP displayed a similar decrease in FRET efficiency after 
c-di-GMP injection that is comparable to previous studies (39). In vitro kinetics of the 
YFP-CFP protein confirmed that the fluorophores do not independently undergo a c-di-
GMP-induced conformation change in since there is no change in the emission ratio 
when c-di-GMP is injected.     
 
PlzAR145D loses conformational change while PlzAR145K behaves similarly to PlzA 
 The YFP-PlzAR145D-CFP protein exhibited no change in the emission ratio after c-
di-GMP injection. Therefore, there was a loss of c-di-GMP-induced conformational 
change by PlzA when the arginine at position 145 was mutated into an aspartic acid, 
shown in Figure 3-4.  However, the YFP-PlzAR145K-CFP protein did have a change in 
the emission ratio, therefore, a structural rearrangement was detected when binding c-
di-GMP and mutating Arg145 into a lysine did not disrupt the c-di-GMP-induced 
conformational change by PlzA.   
 
PlzA and PlzC exist as monomers both bound and unbound to c-di-GMP 
 Using size exclusion chromatography, our lab analyzed the c-di-GMP-bound and 
unbound state of PlzA and PlzC for oligomerization. PlzA and PlzC alone eluted off of 
the column at the monomeric molecular weight. Additionally, after being incubated with 
c-di-GMP, each protein eluted at a molecular weight comparable to the unbound 
protein, indicating that the monomeric state was maintained (Figure 3-5).  
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Figure 3-3. C-di-GMP induced conformational change by PlzA and PlzC detectable 
by FRET. Excitation of FRET proteins was induced with a 425 nm laser beam and 
fluorescence intensity was detected at 480 nm (donor emission) and 530 nm (acceptor 
emission).  Fluorescence intensity was measured at each emission wavelength for 30 s. 
The raw fluorescence intensity measurements over time are displayed in the bottom graph 
of each panel. C-di-GMP was injected into the wells at the 5 s time point . Therefore, a 
change in the emission ratio at 5 s is indicative of a c-di-GMP-induced conformational 
change. The emission ratio of each protein over time can be found in the top graph of each 
panel. YFP-CFP acted as a negative control with no change in the emission ratio. YFP-
YcgR-CFP acted as a positive control, with a change in the emission ratio at the 5 s time 
point. Both YFP-PlzA-CFP and YFP-PlzC-CFP exhibited a change in the emission ratio 
upon addition of c-di-GMP.
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Figure 3-4. FRET analyses of PlzA with a drastic and conservative substitution 
mutation of arginine 145. PlzA substitution mutants of position 145 were introduced 
into the FRET construct to characterize the PlzA c-di-GMP binding domain. FRET 
assays were conducted similarly to Figure 3-3. The YFP-PlzA-CFP graphs on the left 
are for comparison. The R145D substitution mutant protein resulted in an abolishment 
of the change in the emission ratio upon c-di-GMP binding. However, the R145K 
substitution mutant retained the structural rearrangement exhibited by the YFP-PlzA-
CFP protein.  
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Figure 3-5. PlzA and PlzC exist as monomers in both the apo and holo form. Size 
exclusion chromatography results of proteins with and without c-di-GMP on an Superdex-
75 column, detection was with 280 nm absorbance. Specific fractions were collected and 
run on a reverse phase column. Those fractions are denoted by the brackets and the 
reverse phase results of those fractions indicated by the arrow. C-di-GMP  detection was 
with 254 nm absorbance . The PlzA and PlzC alone fractions (panel A and C) saw no 
detection of c-di-GMP. They each eluted at the monomeric molecular weight based on a 
standard curve. Incubation of PlzA and PlzC with an equivalent concentration of c-di-GMP 
was carried out, then run on a gel filtration column. Again, PlzA and PlzC eluted at the 
monomer molecular weight (panel B and D). The protein and c-di-GMP elution fractions 
were then injected onto a reverse phase column to detect for c-di-GMP and confirm that the 
proteins were bound to c-di-GMP. To verify the c-di-GMP retention volume, an equal 
concentration and volume of c-di-GMP was run on the gel filtration column and the elution 
fraction run on the reverse phase column. The c-di-GMP retention volume off of the gel 
filtration column and the elution volume off of the reverse phase column were consistent 
with the PlzA:c-di-GMP and PlzC:c-di-GMP runs (panel E).
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 To confirm that c-di-GMP was present or absent in the appropriate eluates, 
elution fractions from the size exclusion chromatography were loaded onto a reverse 
phase column to detect the di-nucleotide. A peak at the 18 mL retention volume in the 
protein and c-di-GMP elution fractions of both the PlzA-c-di-GMP and PlzC-c-di-GMP 
run confirmed that c-di-GMP is bound by these proteins. The absence of this peak in the 
protein fraction of the PlzA and PlzC alone runs served as negative controls.  
 
Thermodynamic characterization of the PlzA:c-di-GMP and PlzC:c-di-GMP 
interactions 
 ITC methods were performed to measure the energy usage in maintaining a set 
temperature as the c-di-GMP ligand was titrated into a solution containing the Borrelia 
c-di-GMP receptors. In this way, the amount of heat produced or absorbed by the 
reaction could be detected and a sigmoidal titration curve obtained. From this curve, the 
stoichiometry and affinity of the receptor for the ligand could be calculated. In addition, 
by detecting the energy necessary to return the sample temperature to 25oC. the net 
enthalpy change can be measured from which the net change in entropy can be 
calculated using the Gibbs free energy equation. Thus, the c-di-GMP interactions with 
recombinant PlzA and PlzC were characterized. Raw kinetic measurements of power 
compensation and titration curves can be found in Figure 3-6. Based on the data, the 
dissociation constant of PlzA:c-di-GMP was calculated to be 6.25±1.10 µM and PlzC:c-
di-GMP was 5.92±0.963 µM. The binding stoichiometries of both associations were 
~1:1. These interactions were exothermic and enthalpy-driven, exhibiting high net 
changes in enthalpy and low net changes in entropy. Drastic net entropic changes 
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PlzA:c-di-GMP PlzAR145D:c-di-GMP
PlzAR145K:c-di-GMP
A)
C) D)
B)
PlzC:c-di-GMP
Figure 3-6. PlzA and PlzC bind c-di-GMP with moderate affinity. Isothermal titration 
calorimetry was conducted to characterize the interaction of PlzA, PlzAR145D, PlzAR145K, 
and PlzC with c-di-GMP at 25°C. The top panels depict the raw isotherm titration 
calorimetry data. The bottom panels show the binding isotherm data with calculated, 
dilution-corrected heat release for each reaction with a fit curve using a single site 
interaction model. Thermodynamic profiles of these reactions can be found in Table 3-1.
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would suggest hydrophobic interactions because of a reduced organization of the water 
molecules that interact with the protein surface. However, the PlzA:c-di-GMP and 
PlzC:c-di-GMP ITC data indicate that the heat release in these reactions is due to 
hydrogen bond formation, not hydrophobic interactions. The complete thermodynamic 
profile of PlzA:c-di-GMP and PlzC:c-di-GMP can be found in Table 3-1.  
 For the purpose of the PlzA and PlzC PilZ domain characterization, our lab 
mutated Arg145 into an aspartic acid and lysine residue. The PlzAR145D and PlzAR145K 
interactions with c-di-GMP were measured under the same conditions as PlzA and 
supported the FRET analyses. PlzAR145D exhibited no significant binding events with c-
di-GMP and PlzAR145K binding was comparable to PlzA.  
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Table 3-1. Thermodynamic profiles of PlzA, PlzC, PlzAR145D, and PlzAR145K. 
Syringe: c-di-GMP c-di-GMP c-di-GMP 
Cell: PlzA PlzAR145K PlzC 
Kd (µM) 6.25±1.10  1.18±0.460 5.92±0.963 
N (syringe/cell) 0.91±0.032  0.693±0.026 1.12±0.034 
H (kcal mol-1) -13.7±0.673 -11.6±0.599 -13.7±0.749 
S (cal mol-1 K-1) -22.1 -9.95 -22.0 
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Chapter 4: Discussion 
 
C-di-GMP is a ubiquitous signaling molecule utilized by many bacterial species in 
the regulation of cellular processes (109). Since its discovery 25 years ago, this di-
nucleotide has been implicated in the modulation of many factors contributing to host 
invasion (109). However, it is not c-di-GMP itself that carries out these effector 
functions, but the receptors to which it binds (109).  Therefore, the discovery and 
characterization of these c-di-GMP effectors is highly desirable.  
 Many c-di-GMP receptors contain other recognizable domains, such as the helix-
turn-helix of a DNA binding domain or a membrane fusion domain for ABC transporters 
(81, 109, 143). While PlzA and PlzC each have C-terminal PilZ domains, their 
sequences contain no other clues as to their purpose within the cell since they harbor 
no significant sequence homology to known protein domains. Therefore, insights into 
their potential function and activity must be delineated by examining c-di-GMP effects 
within the Borrelia. 
 Multiple groups have worked to divulge c-di-GMP functionality in the Lyme 
spirochete. Rogers et al. (107) was the first to generate an rrp1 deletion mutant (Δrrp1) 
and eliminate the source of c-di-GMP synthesis. Through transcriptome analysis of 
Δrrp1, it was found that in the absence of the diguanylate cyclase, 140 genes had 
altered expression, which correlates with ~10% of the genome. Several of these genes 
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are involved in motility, chemotaxis, and metabolism, implying that c-di-GMP may 
function to regulate these processes.  
One of the many interesting genes within the Rrp1 regulon is rpoS, one of the 
alternate sigma factors of B. burgdorferi. Specifically, this transcriptional modulation 
appears to be through the oxidative stress response regulator, BosR (133). Decreased 
protein expression of both BosR and RpoS occurred in Δrrp1 (133). How BosR is 
activated to promote RpoS transcription is unknown, but appears to be through a c-di-
GMP effector.  
 Many other studies have found that that both Rrp1 and Hpk1 are upregulated 
during tick feeding (55, 87, 107). This implies that the Rrp1-Hpk1 system may be 
important in the expression of genes significant for spirochete survival in the tick and 
was confirmed experimentally with tick infection studies (62, 71). Thus, it became 
readily apparent that c-di-GMP has a part to play in B. burgdorferi survival within the 
tick. 
One pathway by which c-di-GMP appears to affect tick invasion is through 
activation of the glycerol metabolic pathway (62). An operon of glycerol transport and 
metabolism genes (glp) was reported to be a part of the Rrp1 regulon through multiple 
microarray studies (62, 107). Since glucose is an ample source of nutrients in the 
mammalian host, Δrrp1 would be unaffected during murine infection. However, glycerol 
is likely an important carbon source for the spirochete in the tick vector. A deletion 
mutant was generated in the glp operon to assess if this pathway is the sole cause of 
the altered Δrrp1 phenotype (62). The glp mutant was capable of survival within the tick, 
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albeit at a reduced level (62). This indicates that there is at least one other c-di-GMP-
regulated factor that contributes to B. burgdorferi proliferation in the tick.  
While the absence of c-di-GMP appears to only significantly affect colonization of 
the tick vector, uncontrolled production has a negative effect on both tick and 
mammalian invasion by B. burgdorferi (71, 131, 132).  The pdeA deletion mutant had 
increased intracellular c-di-GMP accumulation and was unable to infect mice even at 
very high bacterial loads (132). Additionally, an Rrp1 overexpression strain was unable 
to infect either the murine or arthropod host (71). This phenotype within the Borrelia is 
consistent with the rest of the bacterial world where high levels of c-di-GMP correlate 
with decreased infectivity (109). 
 Since c-di-GMP signaling in the Borrelia appears to be very important in host 
invasion and enzootic cycle progression, the discovery of the responsible effector 
molecule(s) is vital to delineating the mechanism of c-di-GMP activity. PlzA and PlzC 
are the only confirmed c-di-GMP binding molecules within the Borrelia. Like rrp1, plzA 
transcript levels are upregulated during tick feeding (55). This indicates that factors of 
the bloodmeal induce the transcription of plzA even though it is not within the Rrp1 
regulon (107). Multiple groups have generated plzA mutant strains and each had 
decreased infectivity in mice by needle inoculation as well as decreased colonization of 
the tick by immersion (70, 98). Despite invasion of both the vector and mammalian host, 
albeit mitigated, natural transmission of the spirochete from one host to the other did not 
occur (98). Therefore, a plzA mutant is incapable of completing the enzootic cycle, 
which correlates with the phenotypes of other B. burgdorferi strains with mutated c-di-
GMP-associated genes. In addition to a plzA mutant, Pitzer et al. created a plzA 
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deletion in the pdeA mutant background (98). This strain had detectably higher 
intracellular c-di-GMP levels, but the phenotype of the pdeA and pdeA-plzA deletion 
mutants were identical. Therefore, the non-pathogenic phenotype of the pdeA mutant is 
not because of altered PlzA activity due to bolstered c-di-GMP levels in the spirochete. 
Along with mitigated infectivity, the plzA deletion mutant displayed decreased 
motility speed (70). This phenotype could be accounted for through altered motility gene 
expression or protein-protein interactions with the flagellar motor. Changes in the 
transcription levels of fliG1, cheY3, and fliI by the plzA mutant implicate the former, but 
does not exclude the latter (70). Unlike most other bacterial species, the B. burgdorferi 
genome encodes two motor switch FliG proteins (FliG1 and FliG2, 52). FliG2 appears to 
function as a traditional motor switch protein, localizing to each periplasmic flagellar 
bundle (74). Conversely, FliG1 localizes to one of the poles and, interestingly, a fliG1 
deletion mutant has only one functional flagellar bundle (74). Analysis of the fliG1 
mutant in viscous media revealed that each bundle comprises normal flagellar 
filaments, but only one managed to gyrate, which resulted in severely decreased 
translational motion (74). This presented a unique opportunity to test the necessity of 
motility in B. burgdorferi infectivity without interfering with the architecture that the 
flagella provide (74). Murine infection studies supported that a fliG1 mutant is non-
infectious, reaffirming the significance of motility in spirochetal pathogenicity (25, 74). 
While both motors of the plzA mutant do manage to gyrate in viscous media, the 
translational speed and flexation per second were severely reduced (70). It is tempting 
to speculate that this phenotype is because of altered FliG1 activity due to a lack of 
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PlzA regulation. However, more studies must be conducted on the functionality and 
potential interaction of PlzA with FliG1.  
 In an effort to shed light on the activity and biochemistry of PlzA and the B. 
hermsii homologue, PlzC, this study sought to explore their interaction with c-di-GMP. 
Often, ligand binding induces a conformational change in the receptor and results in an 
alteration in function. A method of detecting this is FRET where the protein in question 
is flanked by a FRET pair. Changes in the relative distance or orientation of the protein 
termini upon ligand binding can be detected by measuring the emission ratio of the 
FRET pair.  
 Through FRET analyses, this study divulged that the only known c-di-GMP 
receptors encoded by the Lyme spirochete, B. burgdorferi, and the TBRF spirochete, B. 
hermsii, exhibit a structural rearrangement when binding c-di-GMP likely significant to 
downstream functions. Both of the PilZ proteins had a decrease in FRET efficiency 
upon addition of c-di-GMP; this could be due to an increase in the distance between the 
amino and carboxyl termini of the protein or simply due to a change in the orientation. 
However, c-di-GMP-induced oligomerization or monomerization of the FRET proteins 
could also result in interference and affect the analysis. Therefore, the potential for PlzA 
and PlzC multimerization had to be assessed. 
 The Pseudomonas putida PilZ domain protein PP4397 has been shown to 
transition from a dimer to a monomer based on c-di-GMP binding (119). When bound by 
PP4397, c-di-GMP occludes the dimeric interface, preventing dimerization (69). 
Therefore, a change in state induced by c-di-GMP binding does occur in other PilZ 
domain proteins. However, size exclusion chromatography of PlzA and PlzC bound and 
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unbound to c-di-GMP upheld that these proteins exist as monomers in the apo and holo 
state. Therefore, the change in FRET efficiency exhibited by PlzA and PlzC is due to 
intramolecular rearrangements upon ligand binding and not intermolecular interactions.  
 Cyclic di-GMP is a freely diffusible molecule and bacteria lack an apparent 
means of physical sequestration in the form of membrane-bound organelles. Therefore, 
varying receptor affinities, intracellular localization, and differential expression levels 
have a key role to play in where and when c-di-GMP affects cell processes (65). A study 
was conducted in S. enterica serovar Typhimurium in which the disparate affinities of 
the only two PilZ domain proteins were found to be significant in governing two different 
cellular processes based on intracellular c-di-GMP concentrations (101). YcgR has 
been implicated in c-di-GMP-induced negative regulation of flagellar rotation through 
protein-protein interactions. This is in order to initiate the transition from motility into 
sessility. YcgR is also a c-di-GMP receptor with one of the highest known PilZ domain 
affinity for c-di-GMP (~190 nM, 37, 101). Alternately, the only other PilZ domain protein, 
BcsA, has a comparatively modest affinity of 8.2 µM. Upon c-di-GMP binding, BcsA 
positively regulates cellulose production, a function that facilitates biofilm formation. 
Therefore, it was hypothesized by Putz et al. that there is a c-di-GMP concentration 
threshold for each of these proteins that must be surpassed before the c-di-GMP-
dependent function can be performed (101). In the case of this study in Salmonella 
Typhimurium, the YcgR threshold is lower so that as c-di-GMP is synthesized motility is 
depressed before the BcsA threshold is reached and cellulose production initiated 
(101).  
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The binding affinities of PlzA and PlzC for c-di-GMP were calculated using 
titration methods. They share a similar affinity, which is not surprising considering the 
high degree of sequence homology between the two. In this study, PlzA’s affinity for c-
di-GMP was calculated to be 6.25 µM and PlzC’s was 5.92 µM. Comparing these 
affinities with the Salmonella PilZ proteins revealed that they are closer to the affinity of 
BcsA than YcgR. However, the phenotype of a plzA mutant more closely correlates with 
YcgR activity in that it affects bacterial motility. Since YcgR interacts with the motor 
switch protein, FliG and FliM, it is appealing to consider that PlzA may act in a similar 
manner.  
 The Borrelia c-di-GMP receptors, PlzA and PlzC, harbor multiple residues that 
are highly conserved among PilZ domain proteins. A sequence comparison of PlzA and 
PlzC to other PilZ domains can be seen in Figure 4-1. Substitution mutations and 
structural determination of other PilZ domains have shown that the two arginines of the 
RxxxR motif directly interact with c-di-GMP, primarily through hydrogen bond formation 
and non-covalent interactions (69). Several other residues also seem to affect c-di-GMP 
binding, these can include those in the DzSxxG motif or other residues more distal in 
sequence from the PilZ domain (37, 56, 69, 81, 113, 115, 119). However, unlike the 
RxxxR, these seem to vary a great deal.  
 In order to further characterize the PilZ domain of PlzA, our lab generated 
recombinant proteins with substitutions of the arginine at position 145, which is the first 
in PlzA’s 145RxxxR motif. The first was a conservative mutation from an arginine to a 
lysine. Both of these amino acids are basic with the two highest isoelectric points of the 
amino acids. Additionally, their structures are alike in that their side chains are similar in 
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PlzA
PlzC
PlzB
VCA0042
DgrB
PA4608
DgrA
PP4397
CesA
YcgR
MrkH
143
143
134
11
7
10
121
572
112
105
187
187
167
44
40
44
162
607
150
145
Figure 4-1. Sequence alignment of the Borrelia PilZ domain proteins with other 
characterized PilZ domain proteins. Alignment was generated by ClustalW 2.0 and 
ESPRIPT. Identical amino acids are highlighted and similar amino acids are surrounded 
by a box. High conservation of the RxxxR/DzSxxG PilZ motif between all proteins, 
including PlzA and PlzC is shown. VCA0042 is PlzD of V. cholera. DgrA and DgrB are 
encoded by Caulobacter crescentus. PA4608 is a P. aeruginosa PilZ domain protein. 
PP4397 is produced by P. putida. CesA is from G. xylinum. MrkH is encoded by 
Azospirillium brasilense. YcgR is a c-di-GMP binding protein associated with motility in 
Salmonella Typhimurium.
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length and end in a positively charged nitrogen-based group, although arginine 
comprises a guanidinium group and lysine, an amino group. The retention of c-di-GMP 
binding and structural rearrangement capabilities must be attributed to the high degree 
of similarity between these two amino acids. The second was a drastic mutation from an 
arginine to an aspartic acid. The difference in the isoelectric points of these two amino 
acids is the most extreme of any pair. This mutation ensured that the localized surface 
charge of the 145RxxxR motif would be significantly altered. Results obtained in this 
study have shown that this mutation did, indeed, not only abolish the conformational 
change, but resulted in no detectable binding of c-di-GMP by PlzA. Other mutations of 
this particular residue within other PilZ domain proteins from an arginine to an alanine 
have also led to abolished c-di-GMP binding (100, 119). The fact that the PlzAR145K 
substitution recombinant protein was still capable c-di-GMP binding and conformational 
change suggests that the interaction is not necessarily primary sequence dependent. 
However, the abolishment of binding in the PlzAR145D protein and retention of binding in 
the PlzAR145K protein indicates that a positively charged at position 145 is very important 
in the PlzA-c-di-GMP interaction. 
 Many PilZ domain proteins contain another arginine residue just upstream of the 
RxxxR motif, making it RRxxxR. Titration studies of these proteins with c-di-GMP have 
revealed that every characterized protein that harbors this additional arginine residue 
binds a c-di-GMP intercalated dimer, including YcgR (37, 56, 69, 113, 115, 119). 
Conversely, if the PilZ domain protein retains a residue other than an arginine at that 
position, the protein binds the monomeric form of c-di-GMP, including PlzD of V. cholera 
(15, 69, 81). Examination of the PlzA and PlzC sequence shows that neither encodes 
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an arginine at this position. The titration analyses in this study revealed that both of 
these bind c-di-GMP with an ~1:1 ratio. An interesting study mutated the residue just 
upstream of the RxxxR motif to encode an arginine in PlzD of V. cholera and 
investigated the binding stoichiometry of this substitution mutant protein to find that the 
ratio had shifted to a 1:2 (69). Considering the conservative metabolic nature of the 
Borrelia with genetic and metabolic materials, it is not surprising that these bacteria 
should evolve to encode a c-di-GMP receptor that only binds one molecule of its ligand 
instead of two. 
While PlzA is the only known c-di-GMP receptor encoded by the Lyme 
spirochete, in comparing the phenotypes of the rrp1 and plzA deletion mutants, it is 
apparent that there may be other c-di-GMP effectors produced by the Lyme spirochete. 
Otherwise, the two mutants would exhibit more comparable phenotypes. Another 
speculation is that PlzA may have functionality independent of c-di-GMP binding. 
Phenotypic characterization of a B. burgdorferi mutant encoding a non-c-di-GMP 
binding PlzA, such as PlzAR145D, would be crucial in elucidating the role of c-di-GMP 
binding by PlzA in vivo. 
 Most research efforts in delineating the c-di-GMP functionality in spirochetal 
regulatory networks has been concentrated in B. burgdorferi and, more recently, B. 
hermsii. However, it is significant to note that there appear to be c-di-GMP networks in 
all of the Borrelia with sequenced genomes (109). Analyses of the B. bissettii, B. afzelii, 
B. valaisiana, B. garinii, B. spielmanii, B. turicatae, B. duttoni, B. recurrentis, and B. 
crocidurae genomes have revealed that these Lyme and relapsing fever spirochetes 
harbor genes that share a great deal of homology with the B. burgdorferi and B. hermsii 
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c-di-GMP systems, including PlzA and PlzC. Additionally, the activity of a PilZ domain 
protein encoded by another pathogenic spirochete, Treponema denticola, was 
investigated very recently (19). The results of this study revealed that a deletion mutant 
of the c-di-GMP receptor TDE0214 exhibited altered motility and reduced biofilm 
formation (19). Research in c-di-GMP signaling by the spirochete is expanding to further 
delineate its potential roles in biochemical processes and pathogenesis.  
In summary, the c-di-GMP regulatory networks of B. burgdorferi and B. hermsii 
have significant involvement in many processes, including motility, metabolism, and 
survival. While the modulation of c-di-GMP levels within the cell through diguanylate 
cyclases and phosphodiesterases is very important for governing downstream effectors, 
c-di-GMP receptors are what perform the mediated functions of this signaling molecule. 
As the only known c-di-GMP binding factors within the Borrelia, the interactions of PlzA 
and PlzC with c-di-GMP are vital in determining the mechanism of c-di-GMP-mediated 
host invasion by the Lyme and relapsing fever spirochetes. In other effectors, the 
mechanism that c-di-GMP alters protein activity literally hinges around the loop-forming 
RxxxR motif into which di-nucleotide nestles. In this study, the structural rearrangement, 
monomeric state, binding stoichiometry, and ligand affinity of PlzA and PlzC were 
determined. These properties must contribute to their function within the cell, which has 
been shown to be significant in motility, infectivity, and enzootic cycle progression.  
Future endeavors in characterizing the c-di-GMP regulatory networks of the 
Borrelia would include detection of c-di-GMP synthesis in vivo during different stages of 
the enzootic cycle. The use of a biosensor with a detectable output would be imperative. 
Studies in Caulobacter crescentus have used a FRET biosensor in this manner (39). 
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Therefore, mutagenesis of the Lyme and relapsing fever spirochetes to express the 
FRET proteins described in this study would further delineate how c-di-GMP functions 
within these bacterial species.  
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